Newron Pharmaceuticals S.p.A. (NP5)

Overview

Newron Pharmaceuticals S.p.A. sets its sights on advancing the treatment landscape for patients grappling with central nervous system (CNS) disorders and pain. This biopharmaceutical firm has carved out a niche for itself in Italy and extended its reach to the United States, carving a path toward redefining patient care with their innovative therapies. Since its inception in 1999, with its headquarters nestled in Bresso, Italy, Newron has been steadfast in its commitment to pioneering novel treatments. Partnering strategically with like-minded entities such as Zambon for the commercialization of its leading product safinamide, and with Meiji Seika Pharma Co., Ltd., for the further research and development, manufacture, and marketing, Newron stands as a beacon of innovation and collaboration in the biopharmaceutical landscape.

Products and Services

Xadago (safinamide)

• A breakthrough in Parkinson's treatment, Xadago is a proprietary chemical entity that has garnered approval across a swath of territories including the European Union, Switzerland, the United Kingdom, the United States, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. This medication has become a cornerstone in the treatment protocols for Parkinson’s disease, offering hope and improved quality of life to those affected.

Evenamide

• This innovative molecule is currently navigating the turbulent waters of a Phase III clinical trial, aspiring to become an adjunct therapy for individuals battling Schizophrenia and treatment-resistant schizophrenia. Evenamide represents Newron's unwavering dedication to addressing unmet needs within the realm of psychiatric disorders, offering a glimmer of hope for a demographic often plagued with limited treatment options.

Ralfinamide

• Delving into the realm of pain management, Ralfinamide is Newron's answer to the pressing need for effective treatments for rare neuropathic pain conditions. Although still under development, Ralfinamide underscores Newron's commitment to expanding its therapeutic horizons and improving the lives of patients suffering from debilitating pain syndromes.